Business Context and Reporting Period
Company: Zevra Therapeutics, Inc. (ZVRA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Zevra is a commercial-stage biopharmaceutical company focused on rare diseases. Its primary commercial assets are MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). The company is also advancing celiprolol for Vascular Ehlers-Danlos syndrome (VEDS) in a Phase 3 trial.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenue, net | $39,663 | $75,883 | $46,282 |
| Net Income | $8,752 | $46,642 | $71,608 |
| Operating Income (Loss) | $16,777 | $68,923 | $(76,401) |
| Cash and Cash Equivalents | $145,321 (as of June 30, 2026) | ||
| Total Investments | $114,858 (as of June 30, 2026) | ||
| Long-Term Debt | $0 (Repaid in Q1 2026) | ||
| Net Cash Provided by Operating Activities | $23,174 (Six months 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 53% year-over-year for the six months ended June 30, 2026 ($75.9M vs. $46.3M), driven by higher MIPLYFFA sales ($54.9M vs. $38.6M) and increased revenue from the global Expanded Access Program (EAP) ($19.1M vs. $5.0M).
- Net Income Decline: Net income decreased to $46.6M for the six months ended June 30, 2026, compared to $71.6M in the prior year. This decrease is primarily due to the absence of a $148.3M one-time gain from the sale of a Priority Review Voucher (PRV) recorded in Q2 2025.
- Debt Extinguishment: The company repaid all outstanding term loans (approx. $63.1M principal) in March 2026, resulting in a $2.8M loss on extinguishment of debt and eliminating long-term debt from the balance sheet.
- Asset Sale: Recorded a $43.3M gain on the sale of future royalties and intellectual property related to the AZSTARYS portfolio to Commave Therapeutics in Q1 2026.
- Cost Reductions: Cost of product revenue decreased significantly ($3.4M vs. $13.7M) due to the absence of a $11.7M inventory write-down recorded in the prior year.
Guidance, Outlook, and Risks
- Regulatory Update (EU): In July 2026, the European Medicines Agency (EMA) adopted a negative opinion regarding the Marketing Authorization Application (MAA) for MIPLYFFA. Zevra has requested a re-examination of this opinion.
- Commercial Strategy: The company is scaling back sales and marketing efforts for OLPRUVA while evaluating strategic alternatives. Focus remains on MIPLYFFA commercialization and the Phase 3 trial for celiprolol (66 enrolled as of June 30, 2026).
- Liquidity: As of June 30, 2026, the company held $260.2M in cash, cash equivalents, and investments. Management believes these resources are sufficient to fund operations for at least the next 12 months.
- Risks: Key risks include the uncertainty of the EU regulatory re-examination, the ability to generate sustained positive operating cash flows, and the potential need for additional capital if product sales or EAP reimbursements underperform.
Investor Verification Checklist
- EU Regulatory Status: Verify the timeline and outcome of the requested re-examination of the EMA's negative opinion on MIPLYFFA.
- OLPRUVA Strategy: Confirm the specific strategic alternatives being evaluated for OLPRUVA given the decision to scale back commercial efforts.
- Cash Runway: Monitor quarterly operating cash flows to ensure the $260M liquidity position remains sufficient without immediate need for equity dilution or debt refinancing.
- Commave Settlement: Review the terms of the Commave Settlement Agreement to understand the cessation of future royalty revenue from the AZSTARYS portfolio.
- Warrant Liability: Track the fair value adjustments of the warrant liability ($13.2M as of June 30, 2026), which impacts non-cash net income.